Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

High-density lipoproteins and atherosclerosis.

Rader DJ.

Am J Cardiol. 2002 Oct 17;90(8A):62i-70i. Review.

PMID:
12419482
2.

High-density lipoproteins: multifunctional vanguards of the cardiovascular system.

Marcil M, O'Connell B, Krimbou L, Genest J Jr.

Expert Rev Cardiovasc Ther. 2004 May;2(3):417-30. Review.

PMID:
15151487
3.

[Metabolism of atherogenic lipoproteins].

Beucler I, Turpin G.

Ann Med Interne (Paris). 2001 Apr;152(3):158-61. Review. French.

PMID:
11431574
4.

High density lipoproteins and coronary heart disease. Future prospects in gene therapy.

Fruchart JC, Duriez P.

Biochimie. 1998 Feb;80(2):167-72. Review.

PMID:
9587674
5.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
6.

How, when, and why to use apolipoprotein B in clinical practice.

Sniderman AD.

Am J Cardiol. 2002 Oct 17;90(8A):48i-54i. Review.

PMID:
12419480
7.

High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease.

Gomaraschi M, Calabresi L, Franceschini G.

Expert Opin Ther Targets. 2006 Aug;10(4):561-72. Review.

PMID:
16848692
8.

Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins.

Malle E, Marsche G, Panzenboeck U, Sattler W.

Arch Biochem Biophys. 2006 Jan 15;445(2):245-55. Epub 2005 Aug 31. Review.

PMID:
16171772
9.

[Antiatherogenic effect of high density lipoprotein].

Turczyn B, SkoczyƄska A.

Postepy Hig Med Dosw. 2002;56(4):499-520. Review. Polish.

PMID:
12418415
10.

Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.

Le Goff W, Guerin M, Chapman MJ.

Pharmacol Ther. 2004 Jan;101(1):17-38. Review.

PMID:
14729390
11.

The rationale for using apoA-I as a clinical marker of cardiovascular risk.

Barter PJ, Rye KA.

J Intern Med. 2006 May;259(5):447-54. Review.

12.

Predictors of atherosclerosis.

Homma Y.

J Atheroscler Thromb. 2004;11(5):265-70. Review.

13.

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM.

Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):481-8. Review. Erratum in: Arterioscler Thromb Vasc Biol 2001 May;21(5):880.

14.

Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.

Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G.

Biochem Soc Trans. 2003 Oct;31(Pt 5):1070-4. Review.

PMID:
14505482
15.

The significance of low-density-lipoproteins size in vascular diseases.

Rizzo M, Berneis K, Corrado E, Novo S.

Int Angiol. 2006 Mar;25(1):4-9. Review.

16.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
17.
18.

Plasma lipoproteins and atherosclerosis.

Tikkanen MJ.

J Diabet Complications. 1990 Apr-Jun;4(2):35-8. Review. No abstract available.

PMID:
2145293
19.
20.

HDL - should we be 'chasing' it now?

Smith EB.

J Hum Nutr. 1980 Feb;34(1):59-62. Review.

PMID:
6987304

Supplemental Content

Support Center